Market
What will be the primary distribution method for Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Hospitals • 25%
Clinics • 25%
Pharmacies • 25%
Community health programs • 25%
Official announcements from pharmaceutical companies or health organizations
Story
Lenacapavir: New Injectable HIV Drug Offers 96-100% Efficacy with Twice-Yearly Dosing, Recognized as Scientific Breakthrough
Dec 30, 2024, 01:30 PM
A new injectable antiretroviral drug, Lenacapavir, has been recognized as a potential breakthrough in the fight against HIV and AIDS. According to reports, it boasts an efficacy rate of 96-100% and offers a twice-yearly dosing schedule, which could significantly enhance treatment accessibility and adherence. This innovation has been highlighted by the journal 'Science' as a scientific breakthrough of the year, with the potential to curb new HIV infections globally. Discussions around its availability and implementation are ongoing, as stakeholders consider the implications of this advancement in HIV prevention and treatment.
View original story
Similar markets
Gilead Sciences • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Sub-Saharan Africa • 25%
South America • 25%
Other • 25%
Southeast Asia • 25%
Regulatory hurdles • 25%
Logistical challenges • 25%
Other • 25%
Funding issues • 25%
Africa • 25%
Europe • 25%
North America • 25%
Asia • 25%
Distribution • 25%
Adherence • 25%
Regulatory approval • 25%
Cost • 25%
Not approved in USA or EU • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Cost • 25%
Regulatory approvals • 25%
Public awareness • 25%
Manufacturing capacity • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Less than 20% • 25%
40% to 60% • 25%
More than 60% • 25%
20% to 40% • 25%